Argente, J., Haqq, A. M., Schorfheide, J. L., Touchot, N., Huber, C., Wiedemann, U., & Pomeroy, J. (2026). Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Wiley. https://doi.org/10.1002/oby.70125
Cita Chicago Style (17a ed.)Argente, Jesús, Andrea M. Haqq, Jan Luca Schorfheide, Nicolas Touchot, Caroline Huber, Urs Wiedemann, y Jeremy Pomeroy. Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Wiley, 2026. https://doi.org/10.1002/oby.70125.
Cita MLA (9a ed.)Argente, Jesús, et al. Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Wiley, 2026. https://doi.org/10.1002/oby.70125.